The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker

Christina Müller; Dejene M. Tufa; Debanjana Chatterjee; Peter F. Mühlradt; Reinhold E. Schmidt; Roland Jacobs

doi:10.1007/s00262-015-1723-3

The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker

Christina Müller, Dejene M. Tufa, Debanjana Chatterjee, Peter F. Mühlradt, Reinhold E. Schmidt, Roland Jacobs

Pediatrics - Blood/Marrow Transplant

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Macrophage-activating lipopeptide-2 (MALP-2) is a potent inducer of proinflammatory cytokine secretion by macrophages, monocytes, and dendritic cells. MALP-2 was reported to be involved in natural killer (NK) cell activation and ensuing tumor rejection. However, the mechanism of MALP-2-mediated NK cell activation remained unclear. Therefore, we studied the effects of MALP-2 on cultured human NK cells. We found that MALP-2 had no direct effect on NK cells. Instead, MALP-2 acted on monocytes and triggered the release of different molecules such as interleukin (IL)-1β, IL-6, IL-10, IL-12, IL-15, interferon gamma-induced protein (IP-10), and prostaglandin (PG)-E2. Our data show that monocyte-derived IP-10 could significantly induce NK cell cytotoxicity as long as the immunosuppression by PGE2 is specifically inhibited by cyclooxygenase (COX)-2 blockade. In summary, our results show that MALP-2-mediated stimulation of monocytes results in the production of several mediators which, depending on the prevailing conditions, affect the activity of NK cells in various ways. Hence, MALP-2 administration with concurrent blocking of COX-2 can be considered as a promising approach in MALP-2-based adjuvant tumor therapies.

Original language	English (US)
Pages (from-to)	1175-1184
Number of pages	10
Journal	Cancer Immunology, Immunotherapy
Volume	64
Issue number	9
DOIs	https://doi.org/10.1007/s00262-015-1723-3
State	Published - Sep 21 2015

Bibliographical note

Funding Information:
The authors would like to extend their sincere appreciation to Sabine Buyny for her help with the chromium release assays. This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG): SFB738/A5, Hannover Biomedical Research School (HBRS), REBIRTH Cluster of Excellence, Niedersächsische Krebsgesellschaft e.V. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2015, Springer-Verlag Berlin Heidelberg.

Keywords

COX-2 upregulation
IP-10
MALP-2
Monocytes
NK cell activation
PGE2

Access

10.1007/s00262-015-1723-3

OpenUrl availability

Full text

Cite this

The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker. / Müller, Christina; Tufa, Dejene M.; Chatterjee, Debanjana et al.
In: Cancer Immunology, Immunotherapy, Vol. 64, No. 9, 21.09.2015, p. 1175-1184.

Research output: Contribution to journal › Article › peer-review

@article{158336d5a38a40509588e1fdfc667da9,

title = "The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker",

abstract = "Macrophage-activating lipopeptide-2 (MALP-2) is a potent inducer of proinflammatory cytokine secretion by macrophages, monocytes, and dendritic cells. MALP-2 was reported to be involved in natural killer (NK) cell activation and ensuing tumor rejection. However, the mechanism of MALP-2-mediated NK cell activation remained unclear. Therefore, we studied the effects of MALP-2 on cultured human NK cells. We found that MALP-2 had no direct effect on NK cells. Instead, MALP-2 acted on monocytes and triggered the release of different molecules such as interleukin (IL)-1β, IL-6, IL-10, IL-12, IL-15, interferon gamma-induced protein (IP-10), and prostaglandin (PG)-E2. Our data show that monocyte-derived IP-10 could significantly induce NK cell cytotoxicity as long as the immunosuppression by PGE2 is specifically inhibited by cyclooxygenase (COX)-2 blockade. In summary, our results show that MALP-2-mediated stimulation of monocytes results in the production of several mediators which, depending on the prevailing conditions, affect the activity of NK cells in various ways. Hence, MALP-2 administration with concurrent blocking of COX-2 can be considered as a promising approach in MALP-2-based adjuvant tumor therapies.",

keywords = "COX-2 upregulation, IP-10, MALP-2, Monocytes, NK cell activation, PGE2",

author = "Christina M{\"u}ller and Tufa, {Dejene M.} and Debanjana Chatterjee and M{\"u}hlradt, {Peter F.} and Schmidt, {Reinhold E.} and Roland Jacobs",

note = "Funding Information: The authors would like to extend their sincere appreciation to Sabine Buyny for her help with the chromium release assays. This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG): SFB738/A5, Hannover Biomedical Research School (HBRS), REBIRTH Cluster of Excellence, Nieders{\"a}chsische Krebsgesellschaft e.V. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: {\textcopyright} 2015, Springer-Verlag Berlin Heidelberg.",

year = "2015",

month = sep,

day = "21",

doi = "10.1007/s00262-015-1723-3",

language = "English (US)",

volume = "64",

pages = "1175--1184",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "9",

}

TY - JOUR

T1 - The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker

AU - Müller, Christina

AU - Tufa, Dejene M.

AU - Chatterjee, Debanjana

AU - Mühlradt, Peter F.

AU - Schmidt, Reinhold E.

AU - Jacobs, Roland

N1 - Funding Information: The authors would like to extend their sincere appreciation to Sabine Buyny for her help with the chromium release assays. This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG): SFB738/A5, Hannover Biomedical Research School (HBRS), REBIRTH Cluster of Excellence, Niedersächsische Krebsgesellschaft e.V. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: © 2015, Springer-Verlag Berlin Heidelberg.

PY - 2015/9/21

Y1 - 2015/9/21

N2 - Macrophage-activating lipopeptide-2 (MALP-2) is a potent inducer of proinflammatory cytokine secretion by macrophages, monocytes, and dendritic cells. MALP-2 was reported to be involved in natural killer (NK) cell activation and ensuing tumor rejection. However, the mechanism of MALP-2-mediated NK cell activation remained unclear. Therefore, we studied the effects of MALP-2 on cultured human NK cells. We found that MALP-2 had no direct effect on NK cells. Instead, MALP-2 acted on monocytes and triggered the release of different molecules such as interleukin (IL)-1β, IL-6, IL-10, IL-12, IL-15, interferon gamma-induced protein (IP-10), and prostaglandin (PG)-E2. Our data show that monocyte-derived IP-10 could significantly induce NK cell cytotoxicity as long as the immunosuppression by PGE2 is specifically inhibited by cyclooxygenase (COX)-2 blockade. In summary, our results show that MALP-2-mediated stimulation of monocytes results in the production of several mediators which, depending on the prevailing conditions, affect the activity of NK cells in various ways. Hence, MALP-2 administration with concurrent blocking of COX-2 can be considered as a promising approach in MALP-2-based adjuvant tumor therapies.

AB - Macrophage-activating lipopeptide-2 (MALP-2) is a potent inducer of proinflammatory cytokine secretion by macrophages, monocytes, and dendritic cells. MALP-2 was reported to be involved in natural killer (NK) cell activation and ensuing tumor rejection. However, the mechanism of MALP-2-mediated NK cell activation remained unclear. Therefore, we studied the effects of MALP-2 on cultured human NK cells. We found that MALP-2 had no direct effect on NK cells. Instead, MALP-2 acted on monocytes and triggered the release of different molecules such as interleukin (IL)-1β, IL-6, IL-10, IL-12, IL-15, interferon gamma-induced protein (IP-10), and prostaglandin (PG)-E2. Our data show that monocyte-derived IP-10 could significantly induce NK cell cytotoxicity as long as the immunosuppression by PGE2 is specifically inhibited by cyclooxygenase (COX)-2 blockade. In summary, our results show that MALP-2-mediated stimulation of monocytes results in the production of several mediators which, depending on the prevailing conditions, affect the activity of NK cells in various ways. Hence, MALP-2 administration with concurrent blocking of COX-2 can be considered as a promising approach in MALP-2-based adjuvant tumor therapies.

KW - COX-2 upregulation

KW - IP-10

KW - MALP-2

KW - Monocytes

KW - NK cell activation

KW - PGE2

UR - http://www.scopus.com/inward/record.url?scp=84939567874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939567874&partnerID=8YFLogxK

U2 - 10.1007/s00262-015-1723-3

DO - 10.1007/s00262-015-1723-3

M3 - Article

C2 - 26036909

AN - SCOPUS:84939567874

SN - 0340-7004

VL - 64

SP - 1175

EP - 1184

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 9

ER -

The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this